Brain Biosciences Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 1
Employees
  • Latest Deal Type
  • Accelerator/​Inc
  • Latest Deal Amount
  • $203K
Latest Deal Amount
  • Investors
  • 1

Brain Biosciences General Information

Description

Manufacturer of brain imaging devices. The company develops portable medical devices for the diagnosis of Alzheimers disease, Frontotemporal Dementia, Lewy Body Dementia, Parkinson's and other neurological and psychiatric disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Diagnostic Equipment
Other Industries
Monitoring Equipment
Primary Office
  • 155 Gibbs Street
  • Unit 520
  • Rockville, MD 20850
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Brain Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 16-Jul-2013 $203K 00000 Completed Startup
To view Brain Biosciences’s complete valuation and funding history, request access »

Brain Biosciences Executive Team (1)

Name Title Board Seat Contact Info
David Beylin Chief Executive Officer
To view Brain Biosciences’s complete executive team members history, request access »

Brain Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Brain Biosciences Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Maryland Industrial Partnerships University Minority 000 0000 000000 0
To view Brain Biosciences’s complete investors history, request access »